These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 23845466)

  • 1. Novel prognostic markers for patients with triple-negative breast cancer.
    Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers of therapeutic resistance in breast cancer.
    Zhou L; Luo Y; Li K; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Jul; 44(7):1421-8. PubMed ID: 23434145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
    Ma JG; Wang NJ; Yu WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
    Demir H; Turna H; Can G; Ilvan S
    J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P; Xu BH; Ma F; Li Q
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
    Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
    Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 expression in triple negative breast cancer.
    Ozkan C; Gumuskaya B; Yaman S; Aksoy S; Guler G; Altundag K
    J BUON; 2012; 17(2):271-6. PubMed ID: 22740205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male breast cancers behave differently in elderly patients.
    Tural D; Selçukbiricik F; Aydoğan F; Beşe N; Yetmen O; Ilvan Ş; Büyükünal E; Serdengeçti S
    Jpn J Clin Oncol; 2013 Jan; 43(1):22-7. PubMed ID: 23159765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.